Is there domestically produced Pembrolizumab?

It is understood that there is no domestic drug Pembrolizumab produced by a domestic pharmaceutical company on the market. However, the original drug pembrolizumab has been approved in many countries for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, lymphoma, etc. However, drug production and marketing may vary by region and country.

Pembrolizumab is a targeted (biological) therapy, which is also called immunotherapy. Pembrolizumab is the non-brand name of the drug. Its trade name is Keytruda, and its Chinese name is Keytruda. Pembrolizumab can be used with chemotherapy. Before a patient starts treatment with pembrolizumab, doctors check cancer tissue levels with a test that uses tissue removed from a biopsy or surgery to measure levels of the protein PD-L1 to determine whether the patient can be treated with the drug.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.